Prognostic significance of insulin-like growth factor binding protein (IGF BP)-4 and IGF BP-5 expression in breast cancer

Japanese Journal of Clinical Oncology

Volumn 37, Issue 8, 2007, Pages 575-582

  Mita, Keiko ^a   Zhang, Zhenhuan ^a   Ando, Yoshiaki ^a   Toyama, Tatsuya ^a   Hamaguchi, Maho ^a   Kobayashi, Shunzo ^a   Hayashi, Shin Ichi ^b   Fujii, Yoshitaka ^a   Iwase, Hirotaka ^c   Yamashita, Hiroko ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Breast cancer; IGFBP 4; IGFBP 5; Prognosis

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN AGONIST; MESSENGER RNA; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HORMONE RELEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENOPAUSE; OVERALL SURVIVAL; POSTOPERATIVE CARE; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA, MESSENGER;

EID: 44849111932     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym066     Document Type: Article

References (29)

1. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005;11:865-70s.
2. Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, Kiyama R, et al. Development of cDNA microarray for expression profiling of estrogen-responsive genes. J Mol Endocrinol 2002;29:175-92.
3. Sachdev D, Yee D. The IGF system and breast cancer. Endocr Relat Cancer 2001;8:197-209.
4. Marshman E, Streuli CH. Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function. Breast Cancer Res 2002;4:231-9.
5. Ali O, Cohen P, Lee KW. Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule. Horm Metab Res 2003;35:726-33.
6. Perks CM, Holly JM. IGFBPs and breast cancer. Breast Dis 2003;17:91-104.
7. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and meta-regression analysis. Lancet 2004;363:1346-53.
8. Cheung PT, Smith EP, Shimasaki S, Ling N, Chernausek SD. Characterization of an insulin-like growth factor binding protein (IGFBP-4) produced by the B104 rat neuronal cell line: Chemical and biological properties and differential synthesis by sublines. Endocrinology 1991;129:1006-15.
9. Kiefer MC, Schmid C, Waldvogel M, Schlapfer I, Futo E, Masiarz FR, et al. Characterization of recombinant human insulin-like growth factor binding proteins 4, 5, and 6 produced in yeast. J Biol Chem 1992;267:12692-9.
10. Neely EK, Rosenfeld RG. Insulin-like growth factors (IGFs) reduce IGF-binding protein-4 (IGFBP-4) concentration and stimulate IGFBP-3 independently of IGF receptors in human fibroblasts and epidermal cells. Endocrinology 1992;130:985-93.
11. Allan GJ, Beattie J, Flint DJ. The role of IGFBP-5 in mammary gland development and involution. Domest Anim Endocrinol 2004;27:257-66.
12. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
13. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21:3357-65.
14. Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y, et al. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 2004;10:6962-8.
15. Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, et al. ATBF1-a messenger RNA expression is correlated with better prognosis in breast cancer. Clin Cancer Res 2005;11:193-8.
16. Bieche I, Laurendeau I, Tozlu S, Olivi M, Vidaud D, Lidereau R, et al. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res 1999;59:2759-65.
17. Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, et al. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 2004;6:R24-30.
18. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-8.
19. Figueroa JA, Jackson JG, McGuire WL, Krywicki RF, Yee D. Expression of insulin-like growth factor binding proteins in human breast cancer correlates with estrogen receptor status. J Cell Biochem 1993;52:196-205.
20. McGuire SE, Hilsenbeck SG, Figueroa JA, Jackson JG, Yee D. Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. Cancer Lett 1994;77:25-32.
21. Yee D, Sharma J, Hilsenbeck SG. Prognostic signi.cance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer. J Natl Cancer Inst 1994;86:1785-9.
22. Rocha RL, Hilsenbeck SG, Jackson JG, Lee AV, Figueroa JA, Yee D. Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: Detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst 1996;88:601-6.
23. Rocha RL, Hilsenbeck SG, Jackson JG, VanDenBerg CL, Weng C, Lee AV, et al. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease-free survival. Clin Cancer Res 1997;3:103-9.
24. Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003;144:4562-74.
25. Wang DY, Fulthorpe R, Liss SN, Edwards EA. Identification of estrogen-responsive genes by complementary deoxyribonucleic acid microarray and characterization of a novel early estrogen-induced gene: EEIG1. Mol Endocrinol 2004;18:402-11.
26. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS. Selective estrogen receptor modulators: Discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 2004;64: 1522-33.
27. Bray SE, Robertson K, Vendrell J, Nguyen C, Purdie CA, Thomson G et al. Tamoxifen failure in breast cancer: Use of gene expression array and immunohistochemistry tissue micro arrays to define a molecular signature of tamoxifen resistance. Breast Cancer Res Treat 2005; 94(suppl 1):5163.
28. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
29. Hao X, Sun B, Hu L, Lahdesmaki H, Dunmire V, Feng Y et al. Differential gene and protein expression in primary breast malignancies and their lymph node metastases as revealed by combined cDNA microarray and tissue microarray analysis. Cancer 2004;100: 1110-22.